SGLT2 INHIBITORS VS. GLP1 AGONISTS AS TREATMENTS FOR OSTEOARTHRITIS

被引：0
|
作者：
Jafarzadeh, S. Reza [1 ]
Ma, Kevin [2 ]
Peloquin, Christine E. [1 ]
Felson, David [1 ]
机构：
[1] Boston Univ, Chobanian & Avedisian Sch Med, Boston, MA USA
[2] Goldman Sch Dent Med, Boston, MA USA
来源：
OSTEOARTHRITIS AND CARTILAGE | 2024年 / 32卷
关键词：
D O I：
暂无
中图分类号：
R826.8 [整形外科学]; R782.2 [口腔颌面部整形外科学]; R726.2 [小儿整形外科学]; R62 [整形外科学（修复外科学）];
学科分类号：
摘要：
051
引用
收藏
页码：S41 / S42
页数：2
相关论文
共 50 条
  • [41] Cardiovascular outcomes with GLP-1 receptor agonists vs. SGLT-2 inhibitors in patients with type 2 diabetes
    Norgaard, Caroline H.
    Starkopf, Liis
    Gerds, Thomas A.
    Vestergaard, Peter
    Bonde, Anders N.
    Fosbol, Emil
    Kober, Lars
    Wong, Nathan D.
    Torp-Pedersen, Christian
    Lee, Christina J-Y
    [J]. EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY, 2022, 8 (06) : 549 - 556
  • [42] Should We Be Combining GLP-1 Receptor Agonists and SGLT2 Inhibitors in Treating Diabetes?
    Packer, Milton
    [J]. AMERICAN JOURNAL OF MEDICINE, 2018, 131 (05): : 461 - 463
  • [43] The Role of Industry and NIH/Academia in the Clinical Development of GLP-1 Agonists and SGLT2 Inhibitors
    Kocak, Brian R.
    Kassir, Zachary
    Luo, Jing
    [J]. DIABETES, 2021, 70
  • [44] Major adverse cardiovascular and limb events in people with diabetes treated with GLP-1 receptor agonists vs SGLT2 inhibitors
    Donna Shu-Han Lin
    An-Li Yu
    Hao-Yun Lo
    Cheng-Wei Lien
    Jen-Kuang Lee
    Wen-Jone Chen
    [J]. Diabetologia, 2022, 65 : 2032 - 2043
  • [45] GLP1 receptor agonist overcomes SGLT2 inhibitor-related overeating
    Matthias Blüher
    [J]. Nature Reviews Endocrinology, 2022, 18 : 523 - 524
  • [46] Major adverse cardiovascular and limb events in people with diabetes treated with GLP-1 receptor agonists vs SGLT2 inhibitors
    Lin, Donna Shu-Han
    Yu, An-Li
    Lo, Hao-Yun
    Lien, Cheng-Wei
    Lee, Jen-Kuang
    Chen, Wen-Jone
    [J]. DIABETOLOGIA, 2022, 65 (12) : 2032 - 2043
  • [47] Kidney and Cardiovascular Outcomes With SGLT2 Inhibitors and/or GLP-1 Receptor Agonists in Type 2 Diabetes
    Neuen, Brendon L.
    Solomon, Scott D.
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2024, 84 (08) : 709 - 711
  • [48] GLP1 receptor agonist overcomes SGLT2 inhibitor-related overeating
    Blueher, Matthias
    [J]. NATURE REVIEWS ENDOCRINOLOGY, 2022, 18 (09) : 523 - 524
  • [49] Cardiovascular outcomes in patients with type 2 diabetes who added either GLP1 receptor agonists or DPP4 inhibitors to SGLT2 inhibitor therapy
    Bykov, Katsiaryna
    Kim, Seoyoung
    Dave, Chintan
    Levin, Raisa
    Wexler, Deborah
    Patorno, Elisabetta
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2022, 31 : 98 - 98
  • [50] Influence of Blood Pressure Management on the Renal Outcome in Patients Treated with SGLT2 Inhibitors and GLP1 Receptor Agonist
    Kobayashi, Kazuo
    Toyoda, Masao
    Kawanami, Daiji
    Tamura, Kouichi
    [J]. DIABETES, 2024, 73
12345